Veru Inc. (NasdaqCM:VERU) announced that it has engaged Morgan Stanley & Co. LLC as a financial advisor to assist the Company and its management in pursuing strategic alternatives regarding its legacy FC2 Female Condom® /FC2 Internal Condom business (FHC Business). Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer said, “The FHC Business has been a great business for Veru. Fiscal year 2020 was a record year in terms of net revenues of $41 million and gross profit of $29 million, and First Quarter fiscal year 2021 is already off on another record-setting pace. The cash flow generated by the FHC Business has allowed Veru to significantly advance its biopharmaceutical clinical programs. We are open to exploring the right kind of strategic transaction for the FHC Business with a view towards the best, long-term interests of Veru shareholders, which may include continuing to operate the FHC Business if we ultimately decide that is in our shareholders’ best interests".